Ticker: GALT

Galectin Therapeutics Inc. (NASDAQ: GALT) - What's happening inside Straight to the point: the company is winding down its large NAVIGATE clinical spend, improving near‑term cash burn, but remains highly levered to related‑party financing and dependent on new capital. Clinical data are mixed - en...